Trial Profile
Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 04 Jul 2014 New trial record